Cardiovascular efficacy of sodium-glucose co-transporter-2 inhibitors and angiotensin receptor neprilysin inhibitors in patients with heart failure according to mineralocorticoid r

Collectively, despite being reasonable, a treatment combination of SGLT-2 inhibitors or sacubitril/valsartan with MRAs does not provide additional cardiovascular benefits for patients with HF with reduced or preserved ejection fraction. Potentially synergistic effects of these drug classes have to be confirmed.